41 St. Joseph's Health Care London and University of Western Ontario, London, Ontario, Canada Objective The 1980 American College of Rheumatology (ACR) classification criteria for systemic sclerosis ...
Background: AR882 is a novel, potent and selective uric acid transporter 1 (URAT1) inhibitor in Phase 2 development for the treatment of hyperuricemia and gout. In Phase 1 healthy subject studies, ...
15 Amsterdam Rheumatology and Immunology Centre, Reade, Amsterdam, The Netherlands Objectives We sought to investigate whether genetic effects on response to TNF inhibitors (TNFi) in rheumatoid ...
Objective Macrophage activation syndrome (MAS) is a life-threatening complication of systemic juvenile idiopathic arthritis (sJIA) characterised by a vicious cycle of immune amplification that can ...
Background Increased levels of the tumour necrosis factor (TNF) -ligand APRIL (A Proliferation Inducing Ligand) were found in synovial fluid and serum of patients with inflammatory arthritis pointing ...
Background: We have previously found promise in NMR as a tool to distinguish sera of active from inactive inflammatory myositis (IIM)1. To understand the changes previously found in sera and urine we ...
Correspondence to Dr. Nunzio Bottini, Dept. of Medicine, University of California San Diego, MC0656, La Jolla, CA 92093, USA; nbottini{at}ucsd.edu; Professor Costantino Pitzalis, William Harvey ...
2 Medical University of Vienna, Division of Rheumatology, Internal Medicine 3 Department, Vienna, Austria 3 Medical University of Vienna, Division of Rheumatology, Internal Medicine 3 Departmet, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback